Payment overview · 2025
General Payments
$672.19
22 reported records · 13 companies
Healthcare provider profile · identity verified
Benjamin Laurence Ho, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · MACON, GA · NPI 1982015939
Verified facts
What the public records show
CMS Open Payments records show Benjamin Laurence Ho, M.D. received $672.19 in general payments during 2025 across 22 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 20.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 163 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $134.65 | 20.0% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $132.98 | 19.8% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $120.23 | 17.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $50.81 | 7.6% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $46.41 | 6.9% | 2 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $42.47 | 6.3% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $33.67 | 5.0% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $23.46 | 3.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.58 | 3.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.06 | 2.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $18.18 | 2.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.07 | 2.2% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.62 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $672.19 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $134.65 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $120.23 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $54.05 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $50.81 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $46.41 | 2 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $42.47 | 2 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $33.67 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $31.77 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $23.46 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $20.58 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $20.58 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $19.06 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $19.04 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $18.18 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $18.18 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $18.18 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $18.18 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $18.18 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.07 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 34 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 99 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 163 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 75 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
37 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
53 | 15 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
99 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
99 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
163 | 23 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
75 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
34 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 313 | 83 |
| Atorvastatin Calcium | Atorvastatin Calcium | 299 | 70 |
| Amlodipine Besylate | Amlodipine Besylate | 278 | 73 |
| Mounjaro | Tirzepatide | 163 | 23 |
| Pantoprazole Sodium | Pantoprazole Sodium | 145 | 35 |
| Gabapentin | Gabapentin | 129 | 35 |
| Metformin Hcl Er | Metformin Hcl | 122 | 36 |
| Irbesartan | Irbesartan | 115 | 31 |
| Lisinopril | Lisinopril | 113 | 27 |
| Montelukast Sodium | Montelukast Sodium | 111 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 109 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 103 | 39 |
| Alendronate Sodium | Alendronate Sodium | 101 | 30 |
| Losartan Potassium | Losartan Potassium | 100 | 25 |
| Jardiance | Empagliflozin | 99 | 23 |
| Carvedilol | Carvedilol | 91 | 25 |
| Chlorthalidone | Chlorthalidone | 83 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 83 | 26 |
| Potassium Chloride | Potassium Chloride | 77 | 18 |
| Ozempic | Semaglutide | 75 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 74 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 71 | 26 |
| Levothyroxine Sodium | Levothyroxine Sodium | 68 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 64 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 63 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 62 | 21 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 62 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 60 | 14 |
| Famotidine | Famotidine | 59 | 12 |
| Metformin Hcl | Metformin Hcl | 59 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 59 | 11 |
| Trazodone Hcl | Trazodone Hcl | 56 | 14 |
| Farxiga | Dapagliflozin Propanediol | 53 | 15 |
| Tramadol Hcl | Tramadol Hcl | 53 | 18 |
| Omeprazole | Omeprazole | 52 | 16 |
| Meloxicam | Meloxicam | 49 | 14 |
| Bumetanide | Bumetanide | 46 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 46 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 45 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | 13 |
| Furosemide | Furosemide | 42 | 13 |
| Bupropion Xl | Bupropion Hcl | 41 | 11 |
| Topiramate | Topiramate | 41 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 40 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 39 | 11 |
| Levetiracetam | Levetiracetam | 39 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 38 | suppressed |
| Linzess | Linaclotide | 37 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 36 | 12 |
| Clonazepam | Clonazepam | 35 | suppressed |
| Telmisartan | Telmisartan | 35 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | suppressed |
| Clonidine | Clonidine | 34 | suppressed |
| Eliquis | Apixaban | 34 | 11 |
| Buspirone Hcl | Buspirone Hcl | 33 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 32 | suppressed |
| Nifedipine Er | Nifedipine | 31 | suppressed |
| Glipizide | Glipizide | 30 | suppressed |
| Ketoconazole | Ketoconazole | 29 | 11 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 28 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 28 | suppressed |
| Hydrocortisone | Hydrocortisone | 27 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 27 | suppressed |
| Rybelsus | Semaglutide | 27 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 27 | suppressed |
| Allopurinol | Allopurinol | 26 | suppressed |
| Alprazolam | Alprazolam | 26 | suppressed |
| Lamotrigine | Lamotrigine | 26 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Ibuprofen | Ibuprofen | 23 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | 13 |
| Spironolactone | Spironolactone | 20 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Simvastatin | Simvastatin | 19 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 18 | 18 |
| Atenolol | Atenolol | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 16 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 17 | 14 |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Lorazepam | Lorazepam | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | 11 |
| Sertraline Hcl | Sertraline Hcl | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Klor-Con M10 | Potassium Chloride | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Prednisone | Prednisone | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 13 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 12 |
| Torsemide | Torsemide | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $672.19 · 22 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | AIRSUPRA, BREZTRI, CAPLYTA, CAPVAXIVE, Cologuard Collection Kit, ELIQUIS, ENFLONSIA, GARDASIL 9, INSPIRE, JARDIANCE, KRYSTEXXA, M-M-R II, MOUNJARO, NURTEC ODT, Ozempic, Qelbree, Rybelsus, VAXNEUVANCE, VRAYLAR, ZORYVE | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error